BR112015001090A2 - composição compreendendo baclofeno e acamprosato, ou sal(is) ou pró-fármaco(s) ou derivado(s) ou formulação(ões) de liberação prolongada dos mesmos; e baclofeno, ou um sal, pró-fármaco, derivado, ou formulação de liberação prolongada do mesmo - Google Patents

composição compreendendo baclofeno e acamprosato, ou sal(is) ou pró-fármaco(s) ou derivado(s) ou formulação(ões) de liberação prolongada dos mesmos; e baclofeno, ou um sal, pró-fármaco, derivado, ou formulação de liberação prolongada do mesmo

Info

Publication number
BR112015001090A2
BR112015001090A2 BR112015001090A BR112015001090A BR112015001090A2 BR 112015001090 A2 BR112015001090 A2 BR 112015001090A2 BR 112015001090 A BR112015001090 A BR 112015001090A BR 112015001090 A BR112015001090 A BR 112015001090A BR 112015001090 A2 BR112015001090 A2 BR 112015001090A2
Authority
BR
Brazil
Prior art keywords
baclofen
prodrug
salt
sustained release
formulation
Prior art date
Application number
BR112015001090A
Other languages
English (en)
Inventor
Cohen Daniel
Chumakov Ilya
Nabirochkin Serguei
Original Assignee
Pharnext
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext filed Critical Pharnext
Publication of BR112015001090A2 publication Critical patent/BR112015001090A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo composição compreendendo baclofeno e acamprosato, ou sal(is) ou pró-fármaco(s) ou derivado(s) ou formulação(ões) de liberação prolongada dos mesmos; e baclofeno, ou um sal, pró-fármaco, derivado, ou formulação de liberação prolongada do mesmo a presente invenção se refere a combinações e métodos para o tratamento de distúrbios de degeneração macular. mais especificamente, a presente invenção se refere a novas terapias combinatórias para a degeneração macular relacionada à idade baseadas na combinação de baclofeno e acamprosato. 1/1
BR112015001090A 2012-07-18 2013-07-18 composição compreendendo baclofeno e acamprosato, ou sal(is) ou pró-fármaco(s) ou derivado(s) ou formulação(ões) de liberação prolongada dos mesmos; e baclofeno, ou um sal, pró-fármaco, derivado, ou formulação de liberação prolongada do mesmo BR112015001090A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261672893P 2012-07-18 2012-07-18
PCT/EP2013/065209 WO2014013025A1 (en) 2012-07-18 2013-07-18 Baclofen and acamprosate based therapy of macular degeneration disorders

Publications (1)

Publication Number Publication Date
BR112015001090A2 true BR112015001090A2 (pt) 2017-06-27

Family

ID=48794112

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015001090A BR112015001090A2 (pt) 2012-07-18 2013-07-18 composição compreendendo baclofeno e acamprosato, ou sal(is) ou pró-fármaco(s) ou derivado(s) ou formulação(ões) de liberação prolongada dos mesmos; e baclofeno, ou um sal, pró-fármaco, derivado, ou formulação de liberação prolongada do mesmo

Country Status (18)

Country Link
US (1) US9545389B2 (pt)
EP (1) EP2874617B1 (pt)
JP (1) JP6271539B2 (pt)
KR (1) KR20150058159A (pt)
CN (1) CN104780917B (pt)
AU (1) AU2013291970B2 (pt)
BR (1) BR112015001090A2 (pt)
CA (1) CA2879114A1 (pt)
EA (1) EA029157B1 (pt)
ES (1) ES2729208T3 (pt)
HK (1) HK1209335A1 (pt)
IL (1) IL236737B (pt)
IN (1) IN2015DN00820A (pt)
MX (1) MX364232B (pt)
NZ (1) NZ704280A (pt)
SG (1) SG11201500309VA (pt)
WO (1) WO2014013025A1 (pt)
ZA (1) ZA201500663B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2727587A1 (en) 2012-10-30 2014-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
EP3062782A1 (en) 2013-10-30 2016-09-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
AU2015217796B2 (en) 2014-02-11 2020-04-30 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
US7109239B2 (en) 2003-08-20 2006-09-19 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
WO2005027950A1 (en) * 2003-09-12 2005-03-31 Ray And Terry's Health Products, Inc. Eye nutritional supplement
DK1716115T3 (da) 2003-12-30 2013-05-27 Xenoport Inc Syntese af acyloxyalkylcarbamat-prodrug og mellemprodukter deraf
EP2117517B1 (en) 2007-01-11 2011-06-01 XenoPort, Inc. Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
JP2010532331A (ja) * 2007-07-05 2010-10-07 アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） 抗痙攣医薬組成物
WO2009033054A1 (en) 2007-09-07 2009-03-12 Xenoport, Inc. Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090082464A1 (en) 2007-09-07 2009-03-26 Bernd Jandeleit Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2009052191A1 (en) 2007-10-15 2009-04-23 Xenoport, Inc. Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2009061934A1 (en) 2007-11-06 2009-05-14 Xenoport, Inc. Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain
WO2009096985A1 (en) 2008-02-01 2009-08-06 Xenoport, Inc. Sustained release particulate oral dosage forms of (r)-baclofen prodrugs and methods of treatment
US20100137442A2 (en) 2008-02-01 2010-06-03 Xenoport, Inc. Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
WO2010089355A1 (en) * 2009-02-04 2010-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
CA2753057C (en) 2009-03-03 2018-09-11 Xenoport, Inc. Sustained release oral dosage forms of an r-baclofen prodrug
EP2419401A2 (en) 2009-04-17 2012-02-22 XenoPort, Inc. GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAb RECEPTOR LIGANDS
DK2560631T3 (da) * 2011-03-01 2014-02-10 Pharnext Baclofen- og acamprosat-baseret af neurologiske forstyrrelser

Also Published As

Publication number Publication date
NZ704280A (en) 2017-06-30
ZA201500663B (en) 2016-10-26
US9545389B2 (en) 2017-01-17
SG11201500309VA (en) 2015-02-27
IN2015DN00820A (pt) 2015-06-12
AU2013291970A1 (en) 2015-02-19
EA201500143A1 (ru) 2015-05-29
EP2874617B1 (en) 2019-02-27
AU2013291970B2 (en) 2017-09-28
MX364232B (es) 2019-04-16
EP2874617A1 (en) 2015-05-27
KR20150058159A (ko) 2015-05-28
MX2015000777A (es) 2015-10-14
EA029157B1 (ru) 2018-02-28
HK1209335A1 (en) 2016-04-01
WO2014013025A1 (en) 2014-01-23
JP6271539B2 (ja) 2018-01-31
JP2015522601A (ja) 2015-08-06
IL236737A0 (en) 2015-02-26
CN104780917A (zh) 2015-07-15
US20150238452A1 (en) 2015-08-27
CA2879114A1 (en) 2014-01-23
CN104780917B (zh) 2017-09-08
ES2729208T3 (es) 2019-10-30
IL236737B (en) 2018-12-31

Similar Documents

Publication Publication Date Title
BR112016004505A2 (pt) uso de uma combinação de pelo menos torasemida e baclofeno, ou sais, pró-fármacos, derivados, ou formulações de liberação sustentada dos mesmos, uso de pelo menos torasemida e baclofeno, ou sais, pró-fármacos, derivados, ou formulações de liberação sustentada dos mesmos, e uso de uma composição compreendendo pelo menos torasemida e baclofeno, ou sais, pró-fármacos, derivados, ou formulações de liberação sustentada dos mesmos
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
BR112015022417A2 (pt) métodos e composições para inibição de proteínas contendo bromodomínio
BR112017011972A2 (pt) derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais
BR112015022041A2 (pt) derivados substituídos de 3-fenilpropilamina para o tratamento de doenças e distúrbios oftálmicas
EA201201321A1 (ru) Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
BR112015007365A2 (pt) Processo para a preparação de um hidrogel, pró-droga ligada a um suporte e composição farmacêutica
BR112015001847A2 (pt) composições e tratamento para doenças e distúrbios nos olhos
BR112016022593A2 (pt) composições e métodos para modular a expressão do fator b do complemento
CO2017003955A2 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
GT201400288A (es) "compuestos de fenoxietil piperidina"
BR112015017759A2 (pt) inibidores de fosfolipase a2 associada à lipoproteína (lp-pla2) à base de 2,3-di-hidroimidazol[1,2-c]pirimidin-5(1h)-ona
GT201400242A (es) "nuevos compuestos de pirazol"
DOP2014000059A (es) Derivados de estra–1,3,5(10),16–tetraen–3–carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
BR112016020260A8 (pt) uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática
BR112016023554A2 (pt) novos compostos macrocíclicos
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112013033831A2 (pt) composição farmacêutica oftalmológica tópica que contém regorafenib
BR112017007138A2 (pt) composto, medicamento, métodos para reduzir proteína 4 de ligação ao retinol e para a profilaxia ou o tratamento de degeneração macular e/ou uma doença, e, uso de um composto.
BR112015030774A2 (pt) novos compostos para o tratamento de câncer
EA201690191A1 (ru) Фармацевтическая композиция для замедленного высвобождения ланреотида
CO7131387A2 (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
CO6351744A2 (es) Sales de n-[6-(cis-2,6-dimetil-morfolin-4-il)-piridini-3-il]-2-metil-4´-(trifluoro-metoxi)-[1,1´-bifenil]-3-carboxamida
BR112015011798A2 (pt) métodos e composições para tratar doenças neurodegenerativas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]